In this fellowship I will develop methods to improve the way drugs are delivered through the use of nanotechnology. Nanoparticles can be used to protect delicate drugs from degrading, and to make sure drugs are delivered where they are required. This helps to lower side effects and improve efficacy of a range of drugs. I lead a multi-disciplinary research team dedicated to understanding of how nanoparticles interact with biological systems, so we can engineer better drug delivery systems.
Innovative And Multi-disciplinary Treatment Strategies For Secondary Degeneration Following Neurotrauma
Funder
National Health and Medical Research Council
Funding Amount
$455,452.00
Summary
Following injury to the central nervous system the damage spreads into nearby areas, leading to worse outcomes for the patient. The research conducted during this Fellowship will ensure that promising treatment strategies to prevent spreading damage are used in the best way, and will determine the mechanism of action of these treatments.
Platform Nanotechnologies For Oral Delivery Of Drugs, Therapeutic Protein And Peptide Delivery
Funder
National Health and Medical Research Council
Funding Amount
$437,034.00
Summary
The development of reliable oral delivery systems for problem drugs and biologics is one of the biggest challenges faced by the pharmaceutical industry in recent times. In order to tackle these challenges, I have developed programmable nanoparticles capable of efficiently deliver wide range of drugs including large peptides and proteins orally.
NEW INSIGHTS IN TREATMENT AND DIAGNOSIS OF GLAUCOMA
Funder
National Health and Medical Research Council
Funding Amount
$419,180.00
Summary
Effective treatment of glaucoma and understanding the exact mechanism of cell death in glaucoma still remain challenging. Here I utilize a smart nanoparticle that could recognize sick cells followed by releasing drugs only to cells that are stressed and need the drug. High-resolution microscopy can map the detailed activity in retina after drug treatments. By doing so, we develop a novel way to deliver drugs to diagnose and treat glaucoma.
A Pharmacological Targeting Approach Implementing Albumin As A Carrier Of A Novel Chemotherapeutic
Funder
National Health and Medical Research Council
Funding Amount
$428,065.00
Summary
Novel agents that bind essential metals have emerged as a potential avenue for cancer therapy. My laboratory has developed potent anti-cancer agents, such as Dp44mT, that bind to the plasma protein, albumin. Notably, the uptake of Dp44mT into tumour cells was increased in the presence of albumin. My research will examine the mechanisms in the albumin-mediated increase in Dp44mT uptake into tumour cells, with the goal to develop albumin nanoparticles to selectively deliver our agents to tumours.
If stem cell transplantation is to be useful to repair brain injury, advancement must be made to improve the delivery, survival and differentiation of transplanted cells so that they can sufficiently integrate into the host brain. Here, self-assembling peptides will be developed to provide physical and biochemical support for stem cells and neurones in cell culture (which may be useful for drug discovery) and following transplantation into the injured brain.
Targeting Inflammation-associated Macrophages For Imaging And Therapy
Funder
National Health and Medical Research Council
Funding Amount
$415,218.00
Summary
Cancer and cardiovascular disease are the most common causes of morbidity and mortality worldwide. The development of effective therapies remains a major challenge and is often associated with severe side-effects. I recently developed novel targeting reagents to effectively deliver therapeutics and diagnostic agents deep inside diseased tissues, such as tumours and atherosclerotic plaques. My research will further explore their therapeutic and imaging applications in cancer and atherosclerosis.
Understanding The Mechanisms Of Nanomedicine Absorption From The Lungs And The Application Of This Knowledge To Improving The Delivery Of Chemotherapeutic Nanomedicines Towards Primary And Secondary Lung Cancers
Funder
National Health and Medical Research Council
Funding Amount
$408,388.00
Summary
The administration of chemotherapeutic 'nanomedicines' via the lungs has the capacity to improve the specific delivery of toxic anti-cancer drugs specifically towards primary and metastatic lung cancers. This project aims to evaluate how nanomedicines are absorbed from the lungs after an inhaled dose, and how they can be best developed as inhaled chemotherapeutics for the treatment of lung cancers.
Improving Cancer Survival By Optimising Drug Exposure At Sites Of Cancer Metastasis
Funder
National Health and Medical Research Council
Funding Amount
$463,652.00
Summary
The metastatic spread of cancer is responsible for 90% of cancer related deaths. While the standard of care is to administer high doses of toxic drugs to kill the cancer, this often leads to life threatening side effects without guarantee of a cure. This work is aimed at identifying how nanometer sized chemotherapeutic ‘nanomedicines’ can be optimally developed to enhance drug targeting towards sites of tumour growth and metastasis and maximise therapeutic success whilst limiting side effects.